Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2016 | (b) 2017 | (c) 2018 | (d) 2019 | (e) 2020 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 36,891,026 | 35,119,963 | 16,438,956 | 20,934,789 | 9,866,077 | 119,250,811 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | 36,891,026 | 35,119,963 | 16,438,956 | 20,934,789 | 9,866,077 | 119,250,811 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | ||||||
| 6 | Public support. Subtract line 5 from line 4. | 119,250,811 | |||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2016 | (b) 2017 | (c) 2018 | (d) 2019 | (e) 2020 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 36,891,026 | 35,119,963 | 16,438,956 | 20,934,789 | 9,866,077 | 119,250,811 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 3,659 | 3,514 | 4,009 | 7,816 | 18,998 | |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | ||||||
| 11 | Total support. Add lines 7 through 10 | 119,269,809 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2016 | (b) 2017 | (c) 2018 | (d) 2019 | (e) 2020 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2016 | (b) 2017 | (c) 2018 | (d) 2019 | (e) 2020 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2020 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2020 |
(iii) Distributable Amount for 2020 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2020 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2019 (reasonable cause required-- explain in Part VI). See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2020: | ||||
| a From 2015....... | ||||
| b From 2016....... | ||||
| c From 2017....... | ||||
| d From 2018....... | ||||
| e From 2019....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2020 distributable amount | ||||
|
i
Carryover from 2015 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2020 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2020 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2020, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2020. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2021. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2016..... | ||||
| b Excess from 2017..... | ||||
| c Excess from 2018..... | ||||
| d Excess from 2019..... | ||||
| e Excess from 2020..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | 20011406 |
| Software Version: | 20.0.2.0 |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| Form 990, Part I, Line 1 | The American Diabetes Association Research Foundation, Inc. the Foundation secures major gifts and grants to fund diabetes-related research. |
| Form 990, Part VI, Section A, Line 1a | The main responsibilities and focus of the Foundations Board is to advance, support and promote charitable contributions by soliciting major gifts for the purpose of funding the American Diabetes Associations nationwide Research Program. The Board of Directors of the Foundation provides governance over the activities of the Foundation in accodance with the purposes, policies and procedures of the American Diabetes Association. The Board delegates to the Foundations Executive Committee responsibililty for management of the Foundation when the Board is not in session. The American Diabetes Association provides complete operational support to the Foundation including staff, facilities and administrative processes. The Foundations annual budget and audit process are governed by the American Diabetes Association Board of Directors and Audit Committee. |
| Form 990, Part VI, Section A, Line 3,7a,7b | The Foundations affairs are managed by the Foundation Board of Directors. The Board of Directors of the Foundation supervises, directs and controls the activities of the Foundation in accordance with the mission, purposes, policies and procedures of the American Diabetes Association. The Board delegates to the Foundations Executive Committee responsibility for management of the Foundation when the Board is in session. The American Diabetes Association provides complete operational support to the Foundation including staff, facilities and administrative processes. The Foundations annual budget and audit process are governed by the American Diabetes Association Board of Directors and Audit Committee. If a vacancy occurs among the Foundations officers for any reason, the Board of Directors of the American Diabetes Association shall fill such position for the unexpired portion of the term. |
| Form 990, Part VI, Section B, Line 11b | IRS Form 990 Review Process by the Governing Body The American Diabetes Association Research Foundation the Foundation draft IRS 990 is reviewed by the American Diabetes Associations management and BDO. The final and signed IRS Form 990 was provided to the Associations Board of Directors and the Foundations Board of Directors prior to filing with the IRS. |
| Form 990, Part VI, Section B, Line 12c | Managing a Conflict of Interest To identify potential conflicts of interest with appropriate due dilligence, the Foundations Officers, Directors and Members of the Grant Review Panel must annually disclose any potential conflicts of interest. The American Diabetes Associations Audit Committee and senior staff in Legal Affairs manage the disclosure and monitoring processes of the Board. The senior staff of the Associations Scientific Medical Division manage the disclosure and monitoring processes of the Grant Review Panel. Through review of the annual disclosure and review of the agendas of relevant Board, Committee and other meetings, appropriate efforts are made in advance of the meetings to identify potential conflicts of interest. Each person also has the responsibility to report his/her own conflicts of interest actual or perceived as those conflicts may arise during a meeting. |
| Form 990, Part VI, Section B, Line 12c | Research Grants Review Committee Conflict of Interest COI within the Research Grants Review Committee is managed through a written COI policy and through COI declarations signed both before and after the review cycle. The COI for grant reviewers is self-reported. The primary considerations addressed in the COI policy and program guidelines are as follows - Institutional Individuals are required to recuse themselves from reviewing grants for scientists at the same institution, including any institutions with which they may be negotiating employment. - Financial Individuals are required to recuse themselves from reviewing grants from which they stand to gain financially if the grant is awarded co-PI, collaborator, subcontracts, etc.. - Personal Individuals are required to recuse themselves from reviewing grants for investigators with whom they either have a personal or professional relationship collaborators, colleagues or personal friends, or a long standing professional or scientific disagreement that prevents them from unbiased review. |
| Form 990, Part VI, Section B, Line 13 | The American Diabetes Association has a written whistleblower policy that applies to the American Diabetes Association Research Foundation. |
| Form 990, Part VI, Section C, Line 17 | Alabama AL97-256 Alaska N/A Arizona10145 Arkansas N/A California CT81471 Colorado 2002-3003670 Connecticut CHR.0005084 Delaware N/A District of Columbia 981855 Florida CH1618 GeorgiaCH-001422 Hawaii N/A Idaho N/A Illinois CO01-025537 Indiana103829 Iowa N/A Kansas 177-257-350 Kentucky ID 45 Louisiana 34629813X Maine CO-1247 Maryland 102 Massachusetts Attorney General 029317 Michigan MICS 10326 Minnesota N/A Mississippi 100000294 Missouri CO- 021-87 Montana N/A Nebraska N/A Nevada N/A New Hampshire 5006New Jersey CH-0581900 New Mexico 1936418 New York 01-30-65 North Carolina SL000618 North Dakota 7894 Ohio 01-0239 Oklahoma 29417396 Oregon16402 Pennsylvania 21 Rhode Island 9500233 South Carolina 641South Dakota N/A Tennessee CO1919 Texas N/A Utah 6536093-CHAR Vermont N/A Virginia N/A Washington 1100167 West Virginia N/A Wisconsin3020-800 WyomingN/A |
| Form 990, Part VI, Section B, Line 14 | The American Diabetes Association has a written Document Retention and Destruction policy that applies to the American Diabetes Research Foundation. |
| Form 990, Part VI, Section C, Line 19 | Document Disclosure The following documents are available on the American Diabetes Association website http//www.diabetes.org Board of Directors, audited Foundation financial statements, IRS Forms 990 and the whistleblower policy. Available subject to request to the American Diabetes Association Legal Affairs Department are the following current bylaws, articles of incorporation and the conflict of interest policy. |
| Form 990, Part VII, Section A, Line 1,2,3 | The Chief Executive Officer is a non-voting member of the Research Foundation Board of Directors. The Chief Executive Officer, the Chief Financial Officer and the Chief Scientific Medical Officer are compensated by the American Diabetes Association based on a standard average of 37.5 hours per week. |
| Form 990, Part VII, Section A, Line 2,4 | Robert Gabbay began his tenure as Chief Scientific Medical Officer on July 1, 2020. Kenneth Moritsugu ended his tenure as Interim Chief Scientific Medical Officer on June 30, 2020. |
| Form 990, Part XI, Line 9 | Other changes in net assets or fund balances of 394,155 reflect prior year research grant award refunds and forfeitures. |
| Form 990, Part VI, Section A, Line 2 | Pearson C. Cummin, III, Secretary-Treasurer, and Linda Cummin, Board of Directors, have a family relationship. |
| Form 990, Part III, Line 4 | Connected for Life |
| Form 990, Part III, Line 4 | Today, more than 122 million Americans in the United States have diabetes or prediabetes an invasive, unrelenting, and debilitating disease that spans all ages, geographic areas, and educational levels. This chronic disease targets children, the elderly, and minority populations more than others and costs the United States 327 billion each year in lost productivity. It is a global epidemic that contributes to heart disease, stroke, nerve and kidney disease, and vision loss. The American Diabetes Association is the only organization dedicated specifically to the research, education, and advocacy required to improve the lives of the 34 million adults and children in the U.S. with diabetes and the 88 million people with prediabetes. For 80 years, we have been working on the front lines to educate at-risk populations protect the rights of people with diabetes at work, school, and other aspects of daily life pioneer clinical and research breakthroughs and foster a pipeline of the best and brightest scientists. |
| Form 990, Part III, Line 4 | The COVID-19 pandemic shined a very bright spotlight on diabetes as a public health crisis and on severe health inequities. For people with diabetes, COVID-19 poses a much greater threat of severe complications, hospitalization, and even death. Throughout 2020, we adapted our resources, programs, and events in service to people living with diabetes and the health care professionals who treat them.From research labs to the halls of the Capitol to the offices of health care practitioners to communities nationwide, the ADA is there. We are bending the curve to help people living with diabetes and their families thrive. Why Because we envision a life free of diabetes and all its burdens, which is fueled by our mission to prevent and cure diabetes and to improve the lives of all people affected by diabetes. |
| Form 990, Part III, Line 4 | DIABETES RESEARCH |
| Form 990, Part III, Line 4 | Diabetes is an extremely complex disease, caused by a combination of various genetic and environmental factors that progressively lead to an inability to produce or effectively utilize insulin. The complexity of causes conspiring to diminish the bodys production or response to insulin, leading to high blood glucose and eventual development of diabetes, makes finding a single cure particularly difficult. While a cure has been elusive, critical research efforts in recent decades have led to significantly improved patient care, resulting in fewer complications and better health outcomes for individuals with diabetes. |
| Form 990, Part III, Line 4 | As a leader in diabetes research, and the only organization dedicated specifically to the research, education, and advocacy required to improve the lives of all people with diabetes, the ADA funds critical, innovative diabetes research and invests in promising scientists early in their careers. Our direct involvement in diabetes research extends back to the 1940s when Dr. Charles H. Best, one of four scientists credited with discovering insulin, provided the ADA with the framework and early leadership for a formalized diabetes research program. |
| Form 990, Part III, Line 4 | Since the ADA started its Research Programs in 1952, we have invested 861 million in more than 4,800 diabetes research projects. In 2020 alone, the ADA supported 258 research projects at 123 leading research institutions across the U.S., all dedicated to progressing the fight against diabetes. Of these projects, 147 were led by in-training or early-career investigators. |
| Form 990, Part III, Line 4 | While we have learned much, there is so much left to discover about diabetes. The primary goals of the ADAs Research Program are toSupport the highest-quality science across the broad spectrum of diabetes research. Support investigators early in their careers to encourage them to dedicate their efforts to diabetes research. Support innovative research with a high potential to have a significant impact for patients with diabetes. In 2020 we also awarded two Cardiovascular-Metabolic Fellowships to Layla A. Abushamat, MD, of the University of Colorado and Jacquelyn M. Walejko, PhD, at Duke University. Their two-year awards, supported by Pfizer, began Jan. 1, 2021. |
| Form 990, Part III, Line 4 | Peer Review Process. One of the factors that sets ADA funded research apart and ensures that we are supporting the very best science is peer review. Peer review is a process whereby grant applications are reviewed and evaluated by individuals who are experts in the field or peers of the individual submitting the grant. ADA grant applications undergo peer review by three or more volunteer experts who are themselves experienced researchers. Reviewers provide both a score and detailed comments regarding the strengths and weaknesses of each grant they review. Scores from all reviewers for each grant are averaged to arrive at a composite merit score that is then used to determine which grants to support. |
| Form 990, Part III, Line 4 | Research ApproachThe ADAs research strategy is targeted and laser focused. This approach is helping us make meaningful, actionable change in specific areas that are highly relevant to the population. In 2020 we focused on COVID19 research and in 2021 we will be emphasizing health disparities and other key initiatives that are aligned with critical societal needs and for those living with diabetes. While we have a targeted approach to funding, we are also continuing to invest in our many career and training awards. Investing in early career diabetes professionals allows us to uplift, support, mentor, and secure the next generation of researchers as they prepare to care for the millions living with diabetes and prediabetes.ADAs research efforts fall broadly into two categories Research and Innovation and Investing in the Future. This ensures we can make the biggest impacts through formative research and intervention development with real world, translational outcomes. |
| Form 990, Part III, Line 4 | COVID19 Research. COVID19 placed extraordinary demands on health care delivery and raised countless questions about the virus effect on people with diabetes. In 2020 the ADA launched a new, targeted research grant program specifically to address the pandemic. We funded 10 research projects from a pool of 212 proposals, awarding up to 100,000 for one year grants starting July 1, 2020. The COVID19 grants support basic, translational, and clinical studies that will be instrumental to better understanding the virus and its complications for those living with diabetes. |
| Form 990, Part III, Line 4 | 2020 Research ProgressThis year ADA-supported researchers made significant progress in understanding how diabetes develops and progresses, and in identifying new ways to combat the disease. |
| Form 990, Part III, Line 4 | Building a Healthy Temple through church-based diabetes education. Researchers have long known that churches can be familiar, comfortable settings to deliver health education. In the African American community, studies suggest this approach improves adherence better than diabetes self management classes held at hospitals or doctors offices. ADA funded researcher Dr. Meizi He wondered if incorporating Christian themes into the intervention, and having church members teach the classes, might deliver more lasting results than traditional faith placed education for U.S. Latinos, 90 percent of whom are affiliated with a church. In 2020 Dr. He recruited and trained church members to deliver a diabetes self management support curriculum, along with a sermon on health and seven sessions of health oriented Bible study. Her initial results were encouraging. The groups run by church members lowered their A1Cs significantly after one year, and they kept their blood sugar blood glucose levels close to or within target range for a full year after the classes ended. The same benefit wasnt seen in those who took classes delivered by certified diabetes educators. Next, Dr. He will apply for funding to turn her research into a curriculum that could be adopted by churches nationwide and accredited by the ADA. |
| Form 990, Part III, Line 4 | Getting to the bottom of hypoglycemia unawareness. One of the most unpleasant, fearsome consequences of diabetes is hypoglycemia, when your blood sugar blood glucose drops dangerously low. Yet after frequent hypoglycemic episodes, some people particularly those with type 1 diabetes develop hypoglycemia unawareness. Without the telltale symptoms, people with diabetes dont know to treat hypoglycemia. With ADA research funding, Dr. Janice Hwang sought to determine whether the brains of people with hypoglycemia unawareness reacted differently to low blood sugar than those of people still sensitive to the bodys signals. The results of the brain scans were obvious. In hypoglycemia sensitive brains, regions connected to cravings and the brains planning and control centers lit up in response to a drop in blood sugar levels. In people with hypoglycemia unawareness, no places in the brain lit up. Ultimately, Dr. Hwangs goal will be to see if hypoglycemia unawareness can be reversed, helping people with diabetes regain the warning systems so critical to glucose management. |
| Form 990, Part III, Line 4 | The next generation of glucose monitoring. When continuous glucose monitors CGM were introduced more than 20 years ago, they represented a huge leap forward in diabetes care, giving people with diabetes a way to monitor their glucose levels in near real time. Research soon showed that CGMs offered people with both type 1 and type 2 diabetes significantly improved blood sugar blood glucose management. Yet only 33 percent of Americans with type 1 diabetes use a CGM, along with just 10 percent of people with type 2. With the help of an ADA grant, Dr. Bing Wang is searching for ways to change that by making CGMs easier to use and less obtrusive. Specifically, hes working to tweak the newer optical sensors to require fewer, if any, finger sticks to calibrate the devices. Dr. Wangs work could be an important building block for future generations of sensors, and it could reduce the pain and fear associated with CGMs. |
| Form 990, Part III, Line 4 | Pathway to Stop Diabetes. The ADAs Pathway to Stop Diabetes is a groundbreaking research initiative that provides critical financial resources, professional mentorship, and scientific guidance to the nations highest impact investigative pioneers. Pathway has an ambitious goal of bringing 100 brilliant scientists to diabetes research, funding a human pathway, and launching the next generation of investigators. inventive, interdisciplinary, progressive, and trailblazing. Pathway provides crucial support to individuals focusing on innovative ideas and transformational approaches that will lead to new discoveries in diabetes prevention and treatment. Since its inception, our Pathway researchers have collectively. Published 170 plus original publications in high impact scientific journals. Filed 13 patent applications, protecting intellectual property to translate discoveries into tools and cures. Delivered 468 engaging and informative presentations and lectures. Founded 3 independent start-ups. |
| Form 990, Part III, Line 4 | Two new Pathway awardees began their research projects in January 2020 Judith Agudo, PhD, Dana Farber Cancer Institute, Boston, MA. Harnessing Immune Privilege Mechanisms from Stem Cells to Protect Stem Cells from Immune Attack. Maxence V. Nachury, PhD, University of California, San Francisco Regulation of Body Weight Homeostasis and B Cell Function by Primary Cilia. Also in 2020, our third group of scientists completed their terms of Pathway funding Zhen Gu, PhD, of the University of California, Los Angeles Marie France Hivert, MD, of Harvard Pilgrim Health Care and Stephen C.J. Parker, PhD, of the University of Michigan. Each of them has already added substantially to our understanding of diabetes and diabetes risk, and their contributions will continue throughout their careers in diabetes science, because they are now set up for success in conducting the kind of innovative, transformative research that holds promise to ultimately stop the health crisis that is diabetes. |
| Form 990, Part III, Line 4 | Scientific SessionsHeld annually, Scientific Sessions exemplifies the ADAs leadership role in the global diabetes community while providing a critical platform for driving diabetes awareness. Scientific Sessions is the worlds largest scientific and medical meeting focused on the latest basic and clinical science research related to diabetes and its complications. |
| Form 990, Part III, Line 4 | For the first time in the ADAs 80 year history, the Scientific Sessions was held online due to the COVID19 pandemic. By translating the in person meeting into an entirely virtual experience, we upheld the ADAs reputation for offering the latest advances in diabetes research, treatment, and care, and hosted a prime setting for researchers and health care professionals to exchange ideas. The virtual 80th Scientific Sessions by the numbers. 12,700 plus professionals, 850 plus presentations, 238 sessions, special lectures, and addresses, 2,409 published abstracts, More than 712 million media impressions generated worldwide through the Communication teams press program media engagement. More than 99 percent of surveyed attendees believed the program was independent, balanced, objective, and scientifically rigorous. Nearly 91 percent said the content gave them the necessary knowledge to enhance their clinical or research practice. |
| Form 990, Part III, Line 4 | Were Connected for Life. The American Diabetes Association is the nations leading voluntary health organization fighting to bend the curve on the diabetes epidemic to help people live a better life and thrive until we ultimately find a cure. The moving force behind the work of the ADA is a network of more than 526,000 volunteers, including our dedicated Board of Directors, a membership of more than 500,000 people with diabetes, their families, and caregivers, the hundreds of thousands of health care professionals we serve across the globe, over 2.7 million email subscribers, as well as nearly 250 staff members. Diabetes has brought us all together, what we do next makes us Connected for Life. Learn more about the American Diabetes Association at diabetes.org. |
| Software ID: | 20011406 |
| Software Version: | 20.0.2.0 |
| Name | Address | EIN | Name control |
|---|---|---|---|
| American Diabetes Association Research Foundation Inc |
2451 Crystal Drive Suite 900 Arlington, VA 22202 |
54-1734511 |
AMER |